A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2011
11/29/2011	CA2507502C Inhibition of inflammation using alpha 7 receptor-binding cholinergic agonists
11/29/2011	CA2494345C Combination of an aromatase inhibitor with a bisphosphonate
11/29/2011	CA2494302C Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
11/29/2011	CA2486910C Ophthalmological use of roflumilast for the treatment of diseases of the eye
11/29/2011	CA2479786C Quinoline derivatives and their use as 5-ht6 ligands
11/29/2011	CA2479711C Formulation
11/29/2011	CA2478645C Treatment of central nervous system damage
11/29/2011	CA2473634C 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
11/29/2011	CA2470447C Streptogramin derivatives, preparation thereof and compositions containing same
11/29/2011	CA2465757C Triazole derivatives as cyclooxygenase (cox) inhibitors
11/29/2011	CA2462580C Utilization of phosphatidylserine in the treatment of attention deficit syndrome (adhs)
11/29/2011	CA2461349C Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
11/29/2011	CA2456327C Multicomponent assemblies having enhanced binding properties for diagnosis and therapy
11/29/2011	CA2453843C Substituted 4-aminocyclohexanol derivatives
11/29/2011	CA2449356C Process for preparing granular compositions
11/29/2011	CA2447811C Glycerol-peg-derivatives as inhibitors of cyclooxygenase-2 and phospholipase-a2
11/29/2011	CA2441858C Arylisoxazoline derivatives, processes for their preparation and their use as pesticides
11/29/2011	CA2440461C Nucleic acid and corresponding protein entitled 161p5c5 useful in treatment and detection of cancer
11/29/2011	CA2438524C Cyclopropaheterocycles as non-nucleoside reverse transcriptase inhibitors
11/29/2011	CA2409076C Composition and method for growing, protecting, and healing tissues and cells
11/29/2011	CA2406080C Antitumoral ecteinascidin derivatives
11/29/2011	CA2401438C Novel human ulip/crmp protein and use thereof in diagnosis and treatment of cancers and paraneoplastic neurological syndromes
11/29/2011	CA2401241C 2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors
11/29/2011	CA2380359C Process for producing benzoxazine derivative and production intermediate thereof
11/29/2011	CA2371226C 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
11/29/2011	CA2233447C Mimicking peptides in cancer therapy
11/28/2011	CA2740537A1 Rapamycin coated expandable devices
11/28/2011	CA2738045A1 Conjugate compounds, methods of making same, and uses thereof
11/28/2011	CA2706292A1 A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
11/27/2011	CA2705685A1 Pharmaceutical dosage form containing an antipsychotic agent
11/24/2011	WO2011146901A1 Pharmaceutical compositions and administrations thereof
11/24/2011	WO2011146886A1 Processes for producing modulators of cystic fibrosis transmembrane conductance regulator
11/24/2011	WO2011146882A1 Chemical compounds, compositions and methods for kinase modulation
11/24/2011	WO2011146876A2 Oral transmucosal administration of sufentanil
11/24/2011	WO2011146863A1 Surgical compositions containing sigma-receptor agonists
11/24/2011	WO2011146850A1 Phenylmorpholines and analogues thereof
11/24/2011	WO2011146829A1 Processes for preparing macrolides and ketolides and intermediates therefor
11/24/2011	WO2011146824A1 Methods and compositions for modulating ocular damage
11/24/2011	WO2011146817A1 Heterocyclic flaviviridae virus inhibitors
11/24/2011	WO2011146808A2 Topical formulation for a jak inhibitor
11/24/2011	WO2011146806A1 Methods for reducing anesthetic-inducible epileptogenic and neurotoxic effects
11/24/2011	WO2011146803A1 Method of treating lung adenocarcinoma with hsp90 inhibitory compounds
11/24/2011	WO2011146801A1 Formulation and dosing of hsp90 inhibitory compounds
11/24/2011	WO2011146768A1 Methods for inhibiting muscle atrophy
11/24/2011	WO2011146732A1 Methods for treating inflammatory autoimmune disorders
11/24/2011	WO2011146726A1 Methods and formulations for oxytocin treatment of substance use, psychiatric and other disorders
11/24/2011	WO2011146712A1 Combination
11/24/2011	WO2011146707A1 Improved process for a folate-targeted agent
11/24/2011	WO2011146635A1 Malignant neoplasm treatment protocol
11/24/2011	WO2011146618A1 Inhibitors of human 12-lipoxygenase
11/24/2011	WO2011146591A1 Substituted hydroxamic acids and uses thereof
11/24/2011	WO2011146583A2 Nanoparticulate cinacalcet formulations
11/24/2011	WO2011146511A1 A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
11/24/2011	WO2011146488A1 Method for purifying a fused pyrrolocarbazole derivative
11/24/2011	WO2011146471A1 Treatment for altitudinal hypoxia
11/24/2011	WO2011146408A1 Hpma polymer platinum chelates
11/24/2011	WO2011146401A1 Novel inhibitors of hepatitis c virus replication
11/24/2011	WO2011146382A1 Improved immunotherapeutic dosing regimens and combinations thereof
11/24/2011	WO2011146371A1 Diazeniumdiolate cyclohexyl derivatives
11/24/2011	WO2011146354A1 Novel prolylcarboxypeptidase inhibitors
11/24/2011	WO2011146336A1 Macrocyclic compounds as trk kinase inhibitors
11/24/2011	WO2011146335A1 Piperidinyl-substituted lactams as gpr119 modulators
11/24/2011	WO2011146324A1 Spiro isoxazoline compounds as sstr5 antagonists
11/24/2011	WO2011146313A1 Pyrazolopyrimidine compounds for the treatment of cancer
11/24/2011	WO2011146287A1 Pyrazolo[4,3-b]pyridine-7-amine inhibitors of alk5
11/24/2011	WO2011146255A1 Combination therapy for the treatment of bacterial infections caused by acinetobacter baumannii
11/24/2011	WO2011146089A1 Modulators of 5-ht receptors and methods of use thereof
11/24/2011	WO2011146031A1 Pharmaceutical composition comprising n- acetylcysteine and a xanthine
11/24/2011	WO2011145993A1 Treatment for reducing inflammation
11/24/2011	WO2011145914A1 Lidocaine as a transformer and producer of transformed complexes of drugs delivered in nano-dosages using injection implants as prolonged release devices
11/24/2011	WO2011145777A1 Pharmaceutical composition including an hif-2α inhibitor as an active ingredient for preventing or treating arthritis
11/24/2011	WO2011145765A1 Skin preparation composition for external use with excellent antibacterial and antifungal effects
11/24/2011	WO2011145747A1 Prodrug of triazolone compound
11/24/2011	WO2011145737A1 Composition for improving condition of skin
11/24/2011	WO2011145735A1 Thiazole derivative
11/24/2011	WO2011145723A1 Method for prevention or treatment of metabolic syndrome
11/24/2011	WO2011145718A1 Novel pyrrolo[2,3-d]pyrimidine compound
11/24/2011	WO2011145669A1 Amide derivative
11/24/2011	WO2011145660A1 Propofol-containing oil-in-water emulsion composition
11/24/2011	WO2011145659A1 Carotenoid-containing composition and production method therefor
11/24/2011	WO2011145642A1 Pharmaceutical composition containing solifenacin
11/24/2011	WO2011145548A1 Crystals of di(arylamino)aryl compound
11/24/2011	WO2011145343A1 Antimalarial drug which contains 5-aminolevulinic acid or derivative thereof as active ingredient
11/24/2011	WO2011145340A1 Prophylactic and/or therapeutic agent for non-alcoholic steatohepatitis
11/24/2011	WO2011145109A1 Dry powder inhalation composition
11/24/2011	WO2011145099A1 Crystalline hydrochloride salt of darunavir
11/24/2011	WO2011145062A1 Treatment of tinnitus and related auditory dysfunctions
11/24/2011	WO2011145035A1 Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
11/24/2011	WO2011145022A1 2-phenyl benzoylamides
11/24/2011	WO2011145019A1 Improved process for diphenylpropylamine derivatives
11/24/2011	WO2011144994A1 Pharmaceutical compositions of nsaid and acid inhibitor
11/24/2011	WO2011144975A1 Multi-unit compositions
11/24/2011	WO2011144787A1 Use of phenolic compounds for the treatment of helicobacter pylori-induced diseases
11/24/2011	WO2011144785A1 Use of poloxamines as inducers of the osteogenic differentiation of mesenchymal cells
11/24/2011	WO2011144777A1 Combination of n-acetylcysteine and lipoic acid for the treatment of a disease with axonal damage and concomitant oxidative lesions
11/24/2011	WO2011144766A1 Pharmaceutical composition of ibuprofen for injection
11/24/2011	WO2011144761A1 Compositions for use in treating or diagnosing bone disorders and/or cardiovascular disorders
11/24/2011	WO2011144751A1 Improved anti-serum albumin binding variants
11/24/2011	WO2011144746A2 Liquid nasal spray containing low-dose naltrexone
11/24/2011	WO2011144745A2 Improved liposomal formulations of lipophilic compounds

1 ... 1465 1466 1467 1468 1469 1470 1471 1472 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 ... 7860